Clinical trial
Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary…
NCT00426751 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00426751 |
|---|---|
| Title | Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI) |
| Official title | Eptifibatide Versus Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infarction, Myocardial |
| Intervention type | Drug |
| Interventions | Abciximab, Eptifibatide |
| Enrollment | 429 |
| Start date | Oct 1, 2006 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Jan 25, 2007 |
| Last update posted | Nov 27, 2012 |
| Countries | France, Germany |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: